Advertisement
ARKG vs IBB
Which ETF would AI Choose? ARK Genomic Revolution ETF (ARKG) vs. iShares Biotechnology ETF (IBB)
Key Takeaways
- ARKG is an actively managed thematic ETF targeting the genomics revolution with concentrated holdings in innovative healthcare companies, while IBB is a passive ETF providing broad exposure to the biotechnology sector.
- ARK Genomic Revolution ETF (ARKG) typically holds 30-40 stocks with heavy concentration in a few genomics-focused names, whereas iShares Biotechnology ETF (IBB) holds over 240 securities for greater diversification.
- Expense ratios differ notably: ARKG charges 0.75%, compared to IBB's 0.44%, reflecting ARKG's active management versus IBB's index-tracking approach.
- Both ETFs allocate nearly 100% to healthcare, but ARKG emphasizes disruptive genomics technologies such as gene editing and bioinformatics, while IBB covers a wider range of established and emerging biotechnology firms.
- ARKG exhibits higher volatility due to its concentrated thematic bets, whereas IBB offers more stable exposure through its modified market-capitalization weighting and broader holdings base.
- Structural differences position ARKG for investors seeking high-conviction innovation exposure and IBB for those preferring cost-efficient, diversified sector access.
Introduction
ARK Genomic Revolution ETF (ARKG) and iShares Biotechnology ETF (IBB) both target healthcare innovation but pursue distinct strategies within the biotechnology space. ARKG focuses on the genomics revolution through active stock selection, while IBB delivers broad, passive exposure to the biotechnology industry via an index-tracking methodology. These ETFs appeal to investors seeking growth in life sciences but differ in risk, cost, and thematic depth. The comparison highlights how active thematic approaches contrast with established sector benchmarks amid ongoing advancements in gene therapies, diagnostics, and drug development.
ARK Genomic Revolution ETF (ARKG) Overview
ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund launched in 2014 that seeks long-term capital growth by investing at least 80% of assets in domestic and foreign equity securities of companies involved in the genomics revolution. The fund typically holds 30-40 stocks, with top positions including 10x Genomics Inc (TXG), Twist Bioscience Corp (TWST), Tempus AI Inc (TEM), CRISPR Therapeutics AG (CRSP), and Absci Corp (ABSI). Holdings concentrate in healthcare, particularly genomics, gene editing, and bioinformatics. The expense ratio stands at 0.75%. As a non-diversified, actively managed vehicle, ARKG features dynamic rebalancing driven by ARK Investment Management's thematic research rather than mechanical index rules.
iShares Biotechnology ETF (IBB) Overview
iShares Biotechnology ETF (IBB) is a passively managed fund launched in 2001 that seeks to track the performance of the NYSE Biotechnology Index, composed of U.S.-listed equities primarily engaged in biotechnology. The ETF holds approximately 240 securities with top holdings such as Gilead Sciences Inc (GILD), Amgen Inc (AMGN), Vertex Pharmaceuticals Inc (VRTX), Regeneron Pharmaceuticals Inc (REGN), and Moderna Inc (MRNA). Sector allocation is almost entirely healthcare, spanning biotechnology, life sciences tools, and pharmaceuticals. The expense ratio is 0.44%. IBB employs modified market-capitalization weighting with quarterly rebalancing to maintain alignment with its benchmark, offering broad diversification across market capitalizations.
Industry and Thematic Backdrop
The biotechnology sector continues to benefit from advances in gene editing, personalized medicine, and AI-driven drug discovery. Regulatory pathways for novel therapies remain active, while macroeconomic factors such as interest rate expectations influence capital flows into growth-oriented healthcare names. Broader risks include clinical trial outcomes, patent expirations, and potential policy changes affecting drug pricing. Both ETFs operate within this environment, with ARKG positioned toward early-stage genomic innovations and IBB capturing established biotechnology leaders alongside emerging players.
Performance and Positioning Comparison
In recent market cycles, ARKG has shown greater sensitivity to sentiment around genomics breakthroughs due to its concentrated active bets, resulting in higher volatility compared to the more stable trajectory of IBB. IBB's diversified holdings across large-cap biotechnology firms have provided relative resilience during sector rotations driven by earnings cycles and macroeconomic shifts. ARKG's thematic focus may amplify gains during periods of innovation momentum, while IBB's passive structure supports consistent exposure with lower turnover. Relative positioning favors IBB for investors prioritizing cost efficiency and breadth, whereas ARKG suits those aligned with specific disruptive themes.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking data-driven insights into ETFs like ARKG and IBB can leverage this platform for informed decision-making.
Tickeron AI Verdict
Based on structural factors including lower expense ratio, broader diversification, and established index methodology, Tickeron’s AI would currently assign a higher probability of favor to iShares Biotechnology ETF (IBB). Its cost efficiency and reduced concentration risk provide a more balanced profile for sustained sector exposure, though ARKG may appeal in environments favoring concentrated thematic momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARKG is a Hold and IBB is a StrongBuy.
ARKG's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ARKG turned positive on October 28, 2026. Looking at past instances where ARKG's MACD turned positive, the stock continued to rise in 47 of 51 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ARKG as a result. In 72 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
ARKG moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARKG crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 22 of 23 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in 248 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 202 of 220 cases where ARKG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for ARKG moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 28 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ARKG broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Momentum Indicator for IBB turns positive, indicating new upward trend
IBB saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 80 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for IBB just turned positive on October 20, 2026. Looking at past instances where IBB's MACD turned positive, the stock continued to rise in 40 of 49 cases over the following month. The odds of a continued upward trend are 82%.
IBB moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IBB crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +2.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBB advanced for three days, in 277 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
IBB broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IBB entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
| ARKG | IBB | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | N/A |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| Advances ODDS (%) | 3 days ago 90% | 3 days ago 85% |
| Declines ODDS (%) | 18 days ago 90% | 9 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 84% |
Advertisement
ARKG and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARKG has been loosely correlated with DNA. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if ARKG jumps, then DNA could also see price increases.
| Ticker / NAME | Correlation To ARKG | 1D Price Change % | ||
|---|---|---|---|---|
| ARKG | 100% | -6.73% | ||
| DNA - ARKG | 62% Loosely correlated | -12.01% | ||
| FATE - ARKG | 60% Loosely correlated | -4.15% | ||
| PHR - ARKG | 59% Loosely correlated | -0.72% | ||
| EDIT - ARKG | 59% Loosely correlated | -8.87% | ||
| BFLY - ARKG | 57% Loosely correlated | -14.91% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TMNS | 49.47 | 0.07 | +0.14% |
| T. Rowe Price Short Municipal Income ETF (TMNS) | |||
| LFDR | 175.79 | N/A | N/A |
| LifeX Durable Income ETF | |||
| IFLO | 36.03 | -0.23 | -0.65% |
| VictoryShares International Free Cash Flow ETF (IFLO) | |||
| FNOV | 60.23 | -0.64 | -1.05% |
| FT Vest U.S. Equity Buffer ETF - November (FNOV) | |||
| SPD | 40.77 | -0.78 | -1.88% |
| Simplify US Equity PLUS Downside Convexity ETF (SPD) | |||